Efficacy and Safety of Alteplase Combined with Urinarykallid for Intravenous Thrombolysis on Acute Cerebral Infarction

This study aimed to explore the efficacy and safety of alteplase combined with urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction. Patients ( n = 125) who were admitted to our hospital were included and divided into Group A ( n = 60) and Group B ( n = 65). Pati...

Full description

Saved in:
Bibliographic Details
Published inNeurochemical journal Vol. 18; no. 1; pp. 226 - 232
Main Authors Jiahui Shao, Bao, Linyi, Jin, Xinchun, Jin, Haimiao, Chen, Yun
Format Journal Article
LanguageEnglish
Published Moscow Pleiades Publishing 01.03.2024
Subjects
Biomedical and Life Sciences
Biomedicine
Clinical Neurochemistry
Neurosciences
safety analysis
urinarykallid
alteplase
acute cerebral infarction
efficacy
Online AccessGet full text

Cover

More Information
Summary:This study aimed to explore the efficacy and safety of alteplase combined with urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction. Patients ( n = 125) who were admitted to our hospital were included and divided into Group A ( n = 60) and Group B ( n = 65). Patients in Group A were treated with alteplase for intravenous thrombolysis, based on which urinarykallid was administered to patients in Group B as a combination treatment. Compared to Group A, Group B was significantly lower in hs-CRP and TNF-α levels ( p < 0.001), total incidence of adverse reactions ( p < 0.05), and NIHSS score ( p  < 0.001) and higher in IL-10 level ( p < 0.001), total effective rate (markedly effective + effective/total cases × 100%. Compared to the single administration of alteplase, the combination of alteplase and urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction can achieve better efficacy at a lower incidence of adverse reactions and play a more significant role in clinical treatment.
ISSN:1819-7124
1819-7132
DOI:10.1134/S1819712424010203